Vanguard Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,150,759 shares of SUPN stock, worth $192 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,150,759
Previous 6,127,907
0.37%
Holding current value
$192 Million
Previous $191 Million
16.4%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$325 Million0.01% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$151 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$90 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$82.2 Million0.11% of portfolio
-
State Street Corp Boston, MA2.19MShares$68.4 Million0.0% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.67B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...